Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with these agents, making it difficult for branded products like Merck & Co.’s Zerbaxa, Allergan’s Avycaz, and Melinta’s Vabomere to gain uptake in earlier lines of therapy. However, rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant GNIs, and, as our primary market research shows, activity against key drug-resistant pathogens is an important driver of brand use. Furthermore, hospital-based infectious disease (ID) specialists report shifts in their approach to treating GNIs in response to the climbing rates of drug resistance.
- What are the most prescribed first-, second-, and third-line therapies for inpatients with a urinary tract infection, nosocomial pneumonia, or complicated intra-abdominal infection?
- How are physicians approaching the treatment of infections caused by drug-resistant pathogens?
- Which clinical and nonclinical factors drive, and prevent, the prescribing of brand agents such as Zerbaxa, Avycaz, and Tygacil? What are the most common therapies that patients receive prior to being prescribed Zerbaxa, Avycaz or Tygacil?
- What will be the impact of the recent approval of Vabomere? What will drive its use and in which populations will it be used? Which current agents will be most affected by its prescribing?
Provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics to more effectively increase or defend your market position.
Markets covered: United States
Primary research: Survey of 104 hospital-based ID specialists in the United States
Key drugs: Avycaz, Zerbaxa, Vabomere, Invanz, Teflaro, Tygacil, Minocin, and other key GNI generic drugs